Researching of cardos activity for chronic heart failure treatment in case of concomitant chronic kidney disease (stage V, conventional hemodialysis)

Aim: comparative investigation of cardos (antibodies to angiotensin II receptor subtype 1 (AT.,) C-terminal fragment), diovan (Valsartan) or both drug combination effects (changing of clinical picture, physical exertion tolerance and quality of life) for treatment chronic heart failure (CHF) patients. Methods. 12-month open-label randomized research was performed. CHF patients (NYHA Class l-ll, n=30) with concomitant chronic kidney disease (stage V, conventional hemodialysis) were randomized (10 patients in each group) for 6-month treatment by cardos (group I, average dose 1,8g/day), diovan (group II, average dose 80mg/day)orboth drug combination (group III, cardos 1,8g/day and diovan 80mg/day). CHD basic treatment was prescribed for all patients. In a 6-month drug crossover between groups I and I was performed, group III was divided into 2 subgroups (subgroup IIIA— cardos, subgroup NIB — diovan) followed by next 6-month treatment. Results. Long-term treatment by cardos has improved functional class (NYHA) of CHF patients with concomitant chronic kidney disease (stage V, conventional hemodialysis). cardos, diovan and both drug combination have demonstrated improvement of physical exertion tolerance, quality of life and patient clinical status during 6-min walking test. Conclusion. Cardos and diovan have shown the same efficacy. Cardos can be used as real alternative in case of ARA administration necessity